Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 32Leukemia, Lymphocytic, Chronic, B-Cell 22Myelodysplastic Syndromes 9Lymphoma, Follicular 8Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Recurrence 5Leukemia, Myelomonocytic, Chronic 5Multiple Myeloma 4Chromosome 17 deletion 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid 3Hematologic Neoplasms 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Breast Neoplasms 2Tumor Lysis Syndrome 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myeloid Malignancy 1Myeloid Malignancies 1

Interventions

Whole-Body Irradiation 14Mycophenolic Acid 14fludarabine phosphate 13Cyclophosphamide 13Cytarabine 11Methotrexate 9Granulocyte Colony-Stimulating Factor 9Filgrastim 9Cyclosporine 8Peripheral Blood Stem Cell Transplantation 7Vincristine 6Thiotepa 6Tacrolimus 6Dexamethasone 6Cord Blood Stem Cell Transplantation 6merphos 5fludarabine 5Mitoxantrone 5Clofarabine 5Calcium Dobesilate 5Busulfan 5Mercaptopurine 4Melphalan 4Leucovorin 4Cladribine 4pegaspargase 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Leukemia, Biphenotypic, Acute × venetoclax × Clear all
NCT04874194 2025-11-03

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

M.D. Anderson Cancer Center

Phase 1/2 Terminated
24 enrolled 15 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
150 enrolled 17 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡